Cargando…

Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma

Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: (11)C-methionine (MET), (11)C-choline, and (18)F-fluorodeoxyglucose. These studies i...

Descripción completa

Detalles Bibliográficos
Autores principales: YANO, Hirohito, SHINODA, Jun, IWAMA, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566704/
https://www.ncbi.nlm.nih.gov/pubmed/28458384
http://dx.doi.org/10.2176/nmc.ra.2016-0312
_version_ 1783258594541568000
author YANO, Hirohito
SHINODA, Jun
IWAMA, Toru
author_facet YANO, Hirohito
SHINODA, Jun
IWAMA, Toru
author_sort YANO, Hirohito
collection PubMed
description Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: (11)C-methionine (MET), (11)C-choline, and (18)F-fluorodeoxyglucose. These studies included aspects such as tumor behavior, diagnosis, grade of malignancy, spread and invasion, viability, and genetic deletions; moreover, they also evaluated PET as a tool for planning radiation therapy (RT) and determining its outcome. MET-PET in particular is considered to be the most informative for diagnosis and therapeutic decision-making for glioma patients; it is therefore considered crucial for brain tumor therapy. MET-PET is expected to be widely used for brain tumor patients going forward.
format Online
Article
Text
id pubmed-5566704
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-55667042017-08-24 Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma YANO, Hirohito SHINODA, Jun IWAMA, Toru Neurol Med Chir (Tokyo) Review Article Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: (11)C-methionine (MET), (11)C-choline, and (18)F-fluorodeoxyglucose. These studies included aspects such as tumor behavior, diagnosis, grade of malignancy, spread and invasion, viability, and genetic deletions; moreover, they also evaluated PET as a tool for planning radiation therapy (RT) and determining its outcome. MET-PET in particular is considered to be the most informative for diagnosis and therapeutic decision-making for glioma patients; it is therefore considered crucial for brain tumor therapy. MET-PET is expected to be widely used for brain tumor patients going forward. The Japan Neurosurgical Society 2017-07 2017-05-01 /pmc/articles/PMC5566704/ /pubmed/28458384 http://dx.doi.org/10.2176/nmc.ra.2016-0312 Text en © 2017 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Review Article
YANO, Hirohito
SHINODA, Jun
IWAMA, Toru
Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title_full Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title_fullStr Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title_full_unstemmed Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title_short Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma
title_sort clinical utility of positron emission tomography in patients with malignant glioma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566704/
https://www.ncbi.nlm.nih.gov/pubmed/28458384
http://dx.doi.org/10.2176/nmc.ra.2016-0312
work_keys_str_mv AT yanohirohito clinicalutilityofpositronemissiontomographyinpatientswithmalignantglioma
AT shinodajun clinicalutilityofpositronemissiontomographyinpatientswithmalignantglioma
AT iwamatoru clinicalutilityofpositronemissiontomographyinpatientswithmalignantglioma